PDF下载 ( 2160 KB)
Effect of sorafenib combined with transcatheter arterial chemoembolization and radiofrequency ablation on the survival of patients with hepatocellular carcinoma
-
摘要: 目的分析索拉非尼联合经肝动脉化疗栓塞术（TACE）和射频消融（RFA）治疗肝细胞癌（HCC）患者的生存期及预后影响因素。方法回顾性分析2012年1月-2016年6月首都医科大学附属北京佑安医院收治的,分别接受索拉非尼单药治疗（n=30）、索拉非尼联合TACE（二联疗法,n=70）,或者索拉非尼联合TACE和RFA（三联疗法,n=121）治疗的221例HCC患者的中位生存期及其预后影响因素。采用Kaplan-Meier法绘制生存曲线,log-rank检验生存曲线是否有差异,Cox比例风险回归模型进行生存率的影响因素分析;不同疗法治疗患者的Child-Pugh分级和BCLC分期比较,采用Wilcoxon秩和检验分析。结果接受三联疗法治疗患者的中位生存时间,较二联疗法（9. 5个月vs 4. 3个月,χ2=12. 77,P=0. 000 4）,或索拉非尼单药治疗组（9. 5个月vs2. 0个月,χ2=16. 69,P <0. 000 1）显著延长。影响疾病进展的危险因素包括患者年龄<60岁,BCLC分期C期,Child-Pugh分级B级、C级,血清AFP> 200 ng/m...Abstract: Objective To analyze the effect of sorafenib combined with transcatheter arterial chemoembolization (TACE) and radiofrequency ablation (RFA) on the survival of patients with hepatocellular carcinoma (HCC) and its prognostic factors.Methods A retrospective analysis was performed on 221 HCC patients who received sorafenib alone (group A) , sorafenib plus TACE (group B) , or sorafenib combined with TACE and RFA (group C) in Beijing YouAn Hospital, Capital Medical University, from January 2012 to June 2016 to investigate their median survival and its prognostic factors.The Kaplan-Meier method was used to plot a survival curve, and the log-rank test was used to test whether there was any difference in the survival curve;the Cox proportional-hazards regression model was used to analyze the influencing factors for survival rate;the Wilcoxon rank sum test was used to compare Child-Pugh class and Barcelona Clinic Liver Cancer (BCLC) stage between the patients treated with different therapies.Results Group C had a significantly longer median survival than group B (9.5 months vs 4.3 months, χ2=12.77, P=0.000 4) and group A (9.5 months vs 2.0 months, χ2=16.69, P<0.000 1) .The risk factors for disease progression were age<60 years, BCLC stage C, Child-Pugh class B, Child-Pugh class C, serum alpha-fetoprotein>200 ng/ml, poor tumor differentiation, tumor diameter>5 cm, and intrahepatic tumor with microvascular invasion or extrahepatic spread, as well as absence of sorafenib-related side events (all P<0.05) .Conclusion Sorafenib combined with TACE and RFA can prolong the survival of HCC patients.Age<60 years and severe tumor burden are poor prognostic factors for disease progression in HCC patients.
-
[1]LI Z, ZHU JY.An interpretation of diagnosis, management, and treatment of hepatocellular carcinoma (V2017) [J].J Clin Hepatol, 2017, 33 (9) :1655-1657. (in Chinese) 李照, 朱继业.《原发性肝癌诊疗规范 (2017年版) 》解读[J].临床肝胆病杂志, 2017, 33 (9) :1655-1657. [2] TEJEDA-MALDONADO J, GARCIA-JUAREZ I, AGUIRRE-VALADEZ J, et al.Diagnosis and treatment of hepatocellular carcinoma:An update[J].World J Hepatol, 2015, 7 (3) :362-376. [3]LO CM, NGAN H, TSO WK, et al.Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma[J].Hepatology, 2002, 35 (5) :1164-1171. [4]TSOCHATZIS EA, GERMANI G, BURROUGHS AK.Transarterial chemoembolization, transarterial chemotherapy, and intra-arterial chemotherapy for hepatocellular carcinoma treatment[J].Semin Oncol, 2010, 37 (2) :89-93. [5]ZHENG J, SUN B, LIU D, et al.Treatment with transcatheter arterial chemoembolization induces an increase of the L-selectin (low) CXCR3+CD8+T cell subset in patients with hepatocellular carcinoma[J].Onco Targets Ther, 2012, 5:103-109. [6]National Health and Family Planning Commission of the People's Republic of China.Diagnosis, management, and treatment of hepatocellular carcinoma (V2017) [J].J Clin Hepatol, 2017, 33 (8) :1419-1431. (in Chinese) 中华人民共和国国家卫生和计划生育委员会.原发性肝癌诊疗规范 (2017年版) [J].临床肝胆病杂志, 2017, 33 (8) :1419-1431. [7]KUDO M.Radiofrequency ablation for hepatocellular carcinoma:updated review in 2010[J].Oncology, 2010, 78 (Suppl1) :113-124. [8]YADA M, MASUMOTO A, MOTOMURA K, et al.Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma[J].World J Gastroenterol, 2014, 20 (35) :12581-12587. [9]LENCIONI R.Loco-regional treatment of hepatocellular carcinoma in the era of molecular targeted therapies[J].Oncology, 2010, 78 (Suppl 1) :107-112. [10]CROCETTI L, BARGELLINI I, CIONI R.Loco-regional treatment of HCC:Current status[J].Clin Radiol, 2017, 72 (8) :626-635. [11]WANG CH, WEY KC, MO LR, et al.Current trends and recent advances in diagnosis, therapy, and prevention of hepatocellular carcinoma[J].Asian Pac J Cancer Prev, 2015, 16 (9) :3595-3604. [12]TEJEDA-MALDONADO J, GARCIA-JUAREZ I, AGUIRRE-VALADEZ J, et al.Diagnosis and treatment of hepatocellular carcinoma:An update[J].World J Hepatol, 2015, 7 (3) :362-376. [13]LEI XF, KE Y, BAO TH, et al.Effect and safety of sorafenib in patients with intermediate hepatocellular carcinoma who received transarterial chemoembolization:A retrospective comparative study[J].World J Clin Cases, 2018, 6 (5) :74-83. [14]ZHANG Y, GAO X, ZHU Y, et al.The dual blockade of METand VEGFR2 signaling demonstrates pronounced inhibition on tumor growth and metastasis of hepatocellular carcinoma[J].J Exp Clin Cancer Res, 2018, 37 (1) :93. [15]BRUIX J, LII C A, LLOVET J.Reply to:"Predictors of sorafenib benefit in patients with hepatocellular carcinoma"[J].JHepatol, 2018, 68 (3) :620-621. [16]BRUIX J, CHENG A L, MEINHARDT G, et al.Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma:Analysis of two phase III studies[J].JHepatol, 2017, 67 (5) :999-1008. [17]CHOI GH, SHIM JH, KIM MJ, et al.Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma:Results of propensity score analyses[J].Radiology, 2013, 269 (2) :603-611. [18]SOHN W, PAIK YH, CHO JY, et al.Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread:Treatment outcome and prognostic factors[J].J Hepatol, 2015, 62 (5) :1112-1121. [19]SAPISOCHIN G, BRUIX J.Reply[J].Hepatology, 2017, 66 (5) :1704-1705. [20]ZHENG SZ, LIU DJ, SUN P, et al.Feasibility and safety of sorafenib treatment in hepatocellular carcinoma patients with spontaneous rupture[J].World J Gastroenterol, 2014, 20 (43) :16275-16281. 期刊类型引用(18)
1. 张振奇，贺莉. 弥散加权成像联合动态对比增强磁共振成像在肝细胞肝癌患者肝动脉化疗栓塞术后肿瘤活性检测中的应用价值. 陕西医学杂志. 2024(06): 773-776+781 . 
百度学术2. 李玉苓，邹东花，杨大伟. 血清25(OH)D_3及外周血维生素D受体水平与晚期肝细胞癌患者索拉非尼靶向治疗疗效及生存情况的关系. 检验医学与临床. 2024(21): 3111-3116 . 百度学术3. 郭文涛，汶芙蓉，李继昌. 经导管动脉栓塞化疗联合局部热消融治疗大肝癌的临床疗效及对患者肝功能和预后的影响. 癌症进展. 2023(01): 108-110 . 百度学术4. 王占奎，陈治远，耿冀洲. 经导管动脉栓塞化疗联合射频消融术治疗原发性肝细胞肝癌的效果观察. 癌症进展. 2022(01): 71-73 . 百度学术5. 兰海涛，黄真婷，王小星. 超选择性肝动脉化疗栓塞术联合阿帕替尼对中晚期原发性肝癌患者血清MMP表达的影响. 数理医药学杂志. 2022(04): 597-599 . 百度学术6. 张艳芳，杨蕾. 评价替吉奥联合索拉非尼对原发性肝癌患者不良情绪及睡眠质量的影响. 世界睡眠医学杂志. 2022(05): 801-803 . 百度学术7. 张鸣镝，白诺，王喜功，李雷. 经导管动脉栓塞化疗联合射频消融术治疗原发性肝细胞肝癌的疗效观察. 中国肿瘤临床与康复. 2022(07): 819-822 . 百度学术8. 魏晓岑. 索拉非尼联合TACE对肝癌患者的免疫功能及甲胎蛋白水平的影响. 中国医学创新. 2022(21): 56-60 . 百度学术9. 张峰，刘敬峰，吴燕. 索拉非尼联合TACE治疗肝癌复发生存期影响因素预测模型建立. 中西医结合肝病杂志. 2022(08): 750-753 . 百度学术10. 谷俊谋，王立博，曾德俊，陆勤伟，董凯，梁若鹏，王维杰，朱荣涛，孙玉岭. 安罗替尼在肝癌中耐药的差异mRNA筛选. 临床肝胆病杂志. 2021(02): 358-363 . 
本站查看11. 孙志刚，曾宝珠，焦勤书，张喜峰，王伟峰，张志华，杜敏. 原发性肝癌患者索拉非尼联合TACE术治疗的有效性及对患者HIF-1α、VEGF、IL-10、IFN-γ的影响. 实用癌症杂志. 2021(05): 810-813 . 百度学术12. 薛凌飞，齐肖飞. 肝动脉插管化疗栓塞联合索拉非尼对肝细胞癌患者血清低氧诱导因子、血管内皮生长因子水平的影响. 中国医学工程. 2021(07): 123-125 . 百度学术13. 冯丽娟，谢建立，花雪娇. 索拉非尼联合肝动脉灌注化疗治疗对晚期肝癌患者肝功能指标及生活质量改善状况的影响. 中国医学创新. 2021(21): 24-28 . 百度学术14. 白洁，王中良. 索拉非尼三联疗法治疗早期肝癌患者的疗效及对生存质量的影响. 中国药物滥用防治杂志. 2021(06): 857-859+863 . 百度学术15. 周闯，叶健文，宋盛平，刘文韬，于龙，薛建锋，赵龙栓，翟文龙. 免疫联合靶向治疗原发性肝细胞肝癌合并胆管癌栓术后复发的临床疗效. 中华消化外科杂志. 2021(S1): 10-14 . 百度学术16. 缪军. 索拉非尼联合恩替卡韦对经TACE治疗HBV相关性肝细胞癌患者肝功能及血清AFP、HBV-DNA水平的影响. 现代医学与健康研究电子杂志. 2020(24): 54-56 . 百度学术17. 张学文，戴朝六. 肝细胞癌合并门静脉癌栓治疗现状与展望. 临床肝胆病杂志. 2019(04): 899-904 . 本站查看18. 黄燊，杨成雷，张志明. 肝细胞癌的靶向治疗. 临床肝胆病杂志. 2019(11): 2573-2577 . 本站查看其他类型引用(5)
-
百度学术
下载:
